Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison.

Douglas, Raymond S; Dailey, Roger; Subramanian, Prem S; Barbesino, Giuseppe; Ugradar, Shoaib; Batten, Ryan; Qadeer, Rana A; Cameron, Chris

Douglas, Raymond S; Dailey, Roger; Subramanian, Prem S; Barbesino, Giuseppe; Ugradar, Shoaib; Batten, Ryan; Qadeer, Rana A; Cameron, Chris.

Afiliação

Douglas RS; Cedars-Sinai Medical Center, Los Angeles, California.
Dailey R; Oregon Health & Science University, Portland.
Subramanian PS; University of Colorado, Aurora.
Barbesino G; Massachusetts General Hospital, Harvard Medical School, Boston.
Ugradar S; Jules Stein Eye Institute, University of California, Los Angeles.
Batten R; EVERSANA, Sydney, Nova Scotia, Canada.
Qadeer RA; EVERSANA, Burlington, Ontario, Canada.
Cameron C; EVERSANA, Sydney, Nova Scotia, Canada.

JAMA Ophthalmol ; 140(4): 328-335, 2022 04 01.

Article em En | MEDLINE | ID: mdl-35175308

Assuntos

Exoftalmia; Oftalmopatia de Graves; Anticorpos Monoclonais Humanizados; Diplopia/diagnóstico; Diplopia/tratamento farmacológico; Exoftalmia/tratamento farmacológico; Oftalmopatia de Graves/diagnóstico; Oftalmopatia de Graves/tratamento farmacológico; Humanos; Metilprednisolona/uso terapêutico

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Exoftalmia / Oftalmopatia de Graves Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Revista: JAMA Ophthalmol Ano de publicação: 2022 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google